Report cover image

Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Type Of Synthesis (Biotech, Synthetic), By Type Of Manufacturer (Captive, Merchant), By Type, By Application, By Type of Drug, By Region, And Segment Forecasts, 2026 - 2033

Publisher Grand View Research
Published Dec 19, 2025
Length 150 Pages
SKU # GV20723873

Description

Active Pharmaceutical Ingredients Market Summary

The global active pharmaceutical ingredients market size was estimated at USD 270.53 billion in 2025 and is expected to reach USD 418.99 billion by 2033, growing at a CAGR of 5.55% from 2026 to 2033.The rising global demand for pharmaceuticals, especially in emerging markets, drives growth due to increasing chronic diseases like cancer, diabetes, and cardiovascular conditions.

Advancements in biologics and biosimilars, along with innovative drug formulations, are further boosting the need for specialized APIs. Moreover, the shift toward generic medicines and the rise in contract manufacturing organizations (CMOs) are accelerating API production and distribution, driving the growth of the active pharmaceutical ingredients industry.

The global geriatric population is increasing. According to the UN, in 2023, people aged 65 and above accounted for approximately 771 million of the population, and the number is expected to reach 994 million by 2030, and 1.6 billion by 2050. The number of older adults is showing the fastest growth in Africa, with a threefold increase estimated in people aged 60 and above, followed by Latin America, which is projected to reach 18.8 billion by 2050. Aging is considered the greatest risk factor for the development of diseases, including cardiovascular and neurological diseases. Thus, the rapidly growing global geriatric population is becoming a high-impact driver for the API market.

The increasing prevalence of infectious diseases and hospital-acquired infections is driving market growth. Additionally, the increasing prevalence of cardiovascular, genetic, and neurological disorders is expected to be a significant driver of market growth. Cardiovascular Diseases (CVDs) are the most prevalent causes of death globally. According to the WHO, cardiovascular diseases cause the deaths of 17.9 million people per day and are expected to cause approximately 25 million deaths by 2030. The increasing epidemiology of lifestyle, aided by the rising number of smokers globally, the growing incidence of obesity, and increasing dietary irregularities, is likely to propel market growth. A recent report by the United Nations (UN) in May 2023 suggests that there has been a 75% increase in the number of girls and 61% in the number of boys with obesity in Europe.

Outsourcing of APIs has become profitable over in-house production. However, this trend took a different turn during the COVID-19 pandemic. Companies are seeking to diversify their API suppliers and manufacturers across different locations, rather than outsourcing to a single manufacturer. Additionally, risk mitigation is achieved through dual sourcing to ensure a continuous supply. Hence, key companies aim to capitalize on this ongoing outsourcing trend with new acquisitions. For instance, in August 2023, EUROAPI announced its acquisition deal with BianoGMP to enhance its CDMO expertise in oligonucleotide manufacturing, a high-growth industry. This further demonstrates the company’s plans for vertical integration.

Global Active Pharmaceutical Ingredients Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the active pharmaceutical ingredients market report based on type of synthesis, type of manufacturer, type, application, type of drug, and region:
  • Type of Synthesis Outlook (Revenue, USD Million, 2021 - 2033)
  • Biotech
  • Biotech APIs, By Type
  • Generic APIs
  • Innovative APIs
  • Biotech APIs, By Product
  • Monoclonal Antibodies
  • Hormones
  • Cytokines
  • Recombinant Proteins
  • Therapeutic Enzymes
  • Vaccines
  • Blood Factors
  • Synthetic
  • Synthetic APIs, By Type
  • Generic APIs
  • Innovative APIs
  • Type of Manufacturer Outlook (Revenue, USD Million, 2021 - 2033)
  • Captive APIs
  • Merchant APIs
  • Merchant APIs, By Type of Synthesis
  • Generic APIs
  • Innovative APIs
  • Merchant APIs, By Type
  • Biotech
  • Synthetic
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Generic APIs
  • Innovative APIs
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Cardiology
  • Oncology
  • CNS and Neurology
  • Orthopedic
  • Endocrinology
  • Pulmonology
  • Gastroenterology
  • Nephrology
  • Ophthalmology
  • Others
  • Type of Drugs Outlook (Revenue, USD Million, 2021 - 2033)
  • Prescription
  • OTC
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Russia
  • Hungary
  • Russia
  • Poland
  • Hungary
  • Sweden
  • Switzerland
  • Portugal
  • Greece
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
  • Vietnam
  • Indonesia
  • Malaysia
  • Taiwan
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Colombia
  • Peru
  • Chile
  • Rest of LATAM
  • Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Egypt
  • Israel
  • Belarus
  • Algeria
  • Jordan
  • Iran
  • Rest of MEA
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

150 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Molecule Type
1.2.2. Disease
1.2.3. Drug Type
1.2.4. Drug Development Type
1.2.5. Formulation
1.2.6. Route of Administration
1.2.7. Prescription Type
1.2.8. Sales Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Biopharmaceutical Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Pricing Analysis
Chapter 4. Biopharmaceutical Market: Molecule Type Business Analysis
4.1. Molecule Type Market Share, 2025 & 2033
4.2. Molecule Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Molecule Type, 2021 to 2033 (USD Million)
4.4. Monoclonal Antibody
4.4.1. Monoclonal Antibody Market, 2021 - 2033 (USD Million)
4.5. Interferon
4.5.1. Interferon Market, 2021 - 2033 (USD Million)
4.6. Insulin
4.6.1. Insulin Market, 2021 - 2033 (USD Million)
4.7. Growth and Coagulation Factor
4.7.1. Growth and Coagulation Factor Market, 2021 - 2033 (USD Million)
4.8. Erythropoietin
4.8.1. Erythropoietin Market, 2021 - 2033 (USD Million)
4.9. Vaccine
4.9.1. Vaccine Market, 2021 - 2033 (USD Million)
4.10. Hormone
4.10.1. Hormone Market, 2021 - 2033 (USD Million)
4.11. Others
4.11.1. Other Type Market, 2021 - 2033 (USD Million)
Chapter 5. Biopharmaceutical Market: Disease Business Analysis
5.1. Disease Market Share, 2025 & 2033
5.2. Disease Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
5.4. Oncology
5.4.1. Oncology Market, 2021 - 2033 (USD Million)
5.5. Blood Disorder
5.5.1. Blood Disorder Market, 2021 - 2033 (USD Million)
5.6. Metabolic Disease
5.6.1. Metabolic Disease Market, 2021 - 2033 (USD Million)
5.7. Infectious Disease
5.7.1. Infectious Disease Market, 2021 - 2033 (USD Million)
5.8. Cardiovascular Disease
5.8.1. Cardiovascular Disease Market, 2021 - 2033 (USD Million)
5.9. Neurological Disease
5.9.1. Neurological Disease Market, 2021 - 2033 (USD Million)
5.10. Immunology
5.10.1. Immunology Market, 2021 - 2033 (USD Million)
5.11. Others
5.11.1. Other Type Market, 2021 - 2033 (USD Million)
Chapter 6. Biopharmaceutical Market: Drug Type Business Analysis
6.1. Drug Type Market Share, 2025 & 2033
6.2. Drug Type Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
6.4. Proprietary (Branded)
6.4.1. Proprietary (Branded) Market, 2021 - 2033 (USD Million)
6.4.2. Biosimilars
6.4.2.1. Biosimilars Market, 2021 - 2033 (USD Million)
Chapter 7. Biopharmaceutical Market: Drug Development Type Business Analysis
7.1. Drug Development Type Market Share, 2025 & 2033
7.2. Drug Development Type Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Drug Development Type, 2021 to 2033 (USD Million)
7.4. Outsource
7.4.1. Outsource Market, 2021 - 2033 (USD Million)
7.5. In-house
7.5.1. In-house Market, 2021 - 2033 (USD Million)
Chapter 8. Biopharmaceutical Market: Formulation Business Analysis
8.1. Formulation Market Share, 2025 & 2033
8.2. Formulation Segment Dashboard
8.3. Market Size & Forecasts and Trend Analysis, by Formulation, 2021 to 2033 (USD Million)
8.4. Injectables (IV, IM, SC)
8.4.1. Injectables (IV, IM, SC) Market, 2021 - 2033 (USD Million)
8.5. Inhalation/Nasal Sprays
8.5.1. Inhalation/Nasal Sprays Market, 2021 - 2033 (USD Million)
8.6. Other Formulations
8.6.1. Other Formulations Market, 2021 - 2033 (USD Million)
Chapter 9. Biopharmaceutical Market: Route of Administration Business Analysis
9.1. Route of Administration Market Share, 2025 & 2033
9.2. Route of Administration Segment Dashboard
9.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
9.4. Parenteral (IV, IM, SC)
9.4.1. Parenteral (IV, IM, SC) Market, 2021 - 2033 (USD Million)
9.5. Inhalation/Nasal
9.5.1. Inhalation/Nasal Market, 2021 - 2033 (USD Million)
9.6. Other Routes
9.6.1. Other Routes Market, 2021 - 2033 (USD Million)
Chapter 10. Biopharmaceutical Market: Prescription Type Business Analysis
10.1. Prescription Type Market Share, 2025 & 2033
10.2. Prescription Type Segment Dashboard
10.3. Market Size & Forecasts and Trend Analysis, by Prescription Type, 2021 to 2033 (USD Million)
10.4. Prescription Medicines
10.4.1. Prescription Medicines Market, 2021 - 2033 (USD Million)
10.5. Over-the-counter (OTC) Medicines
10.5.1. Over-the-counter (OTC) Medicines Market, 2021 - 2033 (USD Million)
Chapter 11. Biopharmaceutical Market: Sales Channel Business Analysis
11.1. Sales Channel Market Share, 2025 & 2033
11.2. Sales Channel Segment Dashboard
11.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
11.4. Retail Pharmacies
11.4.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
11.5. Non-retail
11.5.1. Non-retail Market, 2021 - 2033 (USD Million)
Chapter 12. Biopharmaceutical Market: Regional Estimates & Trend Analysis
12.1. Regional Market Share Analysis, 2025 & 2033
12.2. Regional Market Dashboard
12.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
12.4. North America
12.4.1. North America Biopharmaceutical Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
12.4.2. U.S.
12.4.2.1. Key Country Dynamics
12.4.2.2. Target Disease Prevalence
12.4.2.3. Regulatory Framework
12.4.2.4. Reimbursement Framework
12.4.2.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.4.3. Canada
12.4.3.1. Key Country Dynamics
12.4.3.2. Target Disease Prevalence
12.4.3.3. Regulatory Framework
12.4.3.4. Reimbursement Framework
12.4.3.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.4.4. Mexico
12.4.4.1. Key Country Dynamics
12.4.4.2. Target Disease Prevalence
12.4.4.3. Regulatory Framework
12.4.4.4. Reimbursement Framework
12.4.4.5. Mexico Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.5. Europe
12.5.1. Europe Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.5.2. UK
12.5.2.1. Key Country Dynamics
12.5.2.2. Target Disease Prevalence
12.5.2.3. Regulatory Framework
12.5.2.4. Reimbursement Framework
12.5.2.5. Uk Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.5.3. Germany
12.5.3.1. Key Country Dynamics
12.5.3.2. Target Disease Prevalence
12.5.3.3. Regulatory Framework
12.5.3.4. Reimbursement Framework
12.5.3.5. Germany Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.5.4. France
12.5.4.1. Key Country Dynamics
12.5.4.2. Target Disease Prevalence
12.5.4.3. Regulatory Framework
12.5.4.4. Reimbursement Framework
12.5.4.5. France Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.5.5. Italy
12.5.5.1. Key Country Dynamics
12.5.5.2. Target Disease Prevalence
12.5.5.3. Regulatory Framework
12.5.5.4. Reimbursement Framework
12.5.5.5. Italy Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.5.6. Spain
12.5.6.1. Key Country Dynamics
12.5.6.2. Target Disease Prevalence
12.5.6.3. Regulatory Framework
12.5.6.4. Reimbursement Framework
12.5.6.5. Spain Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.5.7. Denmark
12.5.7.1. Key Country Dynamics
12.5.7.2. Target Disease Prevalence
12.5.7.3. Regulatory Framework
12.5.7.4. Reimbursement Framework
12.5.7.5. Denmark Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.5.8. Sweden
12.5.8.1. Key Country Dynamics
12.5.8.2. Target Disease Prevalence
12.5.8.3. Regulatory Framework
12.5.8.4. Reimbursement Framework
12.5.8.5. Sweden Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.5.9. Norway
12.5.9.1. Key Country Dynamics
12.5.9.2. Target Disease Prevalence
12.5.9.3. Regulatory Framework
12.5.9.4. Reimbursement Framework
12.5.9.5. Norway Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.6. Asia Pacific
12.6.1. Asia Pacific Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.6.2. Japan
12.6.2.1. Key Country Dynamics
12.6.2.2. Target Disease Prevalence
12.6.2.3. Regulatory Framework
12.6.2.4. Reimbursement Framework
12.6.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.6.3. China
12.6.3.1. Key Country Dynamics
12.6.3.2. Target Disease Prevalence
12.6.3.3. Regulatory Framework
12.6.3.4. Reimbursement Framework
12.6.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.6.4. India
12.6.4.1. Key Country Dynamics
12.6.4.2. Target Disease Prevalence
12.6.4.3. Regulatory Framework
12.6.4.4. Reimbursement Framework
12.6.4.5. India Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.6.5. Australia
12.6.5.1. Key Country Dynamics
12.6.5.2. Target Disease Prevalence
12.6.5.3. Regulatory Framework
12.6.5.4. Reimbursement Framework
12.6.5.5. Australia Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.6.6. South Korea
12.6.6.1. Key Country Dynamics
12.6.6.2. Target Disease Prevalence
12.6.6.3. Regulatory Framework
12.6.6.4. Reimbursement Framework
12.6.6.5. South Korea Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.6.7. Thailand
12.6.7.1. Key Country Dynamics
12.6.7.2. Target Disease Prevalence
12.6.7.3. Regulatory Framework
12.6.7.4. Reimbursement Framework
12.6.7.5. Thailand Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.7. Latin America
12.7.1. Latin America Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.7.2. Brazil
12.7.2.1. Key Country Dynamics
12.7.2.2. Target Disease Prevalence
12.7.2.3. Regulatory Framework
12.7.2.4. Reimbursement Framework
12.7.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.7.3. Argentina
12.7.3.1. Key Country Dynamics
12.7.3.2. Target Disease Prevalence
12.7.3.3. Regulatory Framework
12.7.3.4. Reimbursement Framework
12.7.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.8. Middle East and Africa
12.8.1. Middle East and Africa Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.8.2. South Africa
12.8.2.1. Key Country Dynamics
12.8.2.2. Target Disease Prevalence
12.8.2.3. Regulatory Framework
12.8.2.4. Reimbursement Framework
12.8.2.5. South Africa Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.8.3. Saudi Arabia
12.8.3.1. Key Country Dynamics
12.8.3.2. Target Disease Prevalence
12.8.3.3. Regulatory Framework
12.8.3.4. Reimbursement Framework
12.8.3.5. Saudi Arabia Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.8.4. UAE
12.8.4.1. Key Country Dynamics
12.8.4.2. Target Disease Prevalence
12.8.4.3. Regulatory Framework
12.8.4.4. Reimbursement Framework
12.8.4.5. UAE Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.8.5. Kuwait
12.8.5.1. Key Country Dynamics
12.8.5.2. Target Disease Prevalence
12.8.5.3. Regulatory Framework
12.8.5.4. Reimbursement Framework
12.8.5.5. Kuwait Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 13. Competitive Landscape
13.1. Participant Overview
13.2. Company Market Position Analysis
13.3. Company Categorization
13.4. Strategy Mapping
13.5. Company Profiles/Listing
13.5.1. F. Hoffmann-La Roche Ltd
13.5.1.1. Overview
13.5.1.2. Financial Performance
13.5.1.3. Product Benchmarking
13.5.1.4. Strategic Initiatives
13.5.2. Novartis AG
13.5.2.1. Overview
13.5.2.2. Financial Performance
13.5.2.3. Product Benchmarking
13.5.2.4. Strategic Initiatives
13.5.3. AbbVie Inc.
13.5.3.1. Overview
13.5.3.2. Financial Performance
13.5.3.3. Product Benchmarking
13.5.3.4. Strategic Initiatives
13.5.4. Johnson & Johnson Services, Inc.
13.5.4.1. Overview
13.5.4.2. Financial Performance
13.5.4.3. Product Benchmarking
13.5.4.4. Strategic Initiatives
13.5.5. Merck & Co., Inc.
13.5.5.1. Overview
13.5.5.2. Financial Performance
13.5.5.3. Product Benchmarking
13.5.5.4. Strategic Initiatives
13.5.6. Pfizer Inc.
13.5.6.1. Overview
13.5.6.2. Financial Performance
13.5.6.3. Product Benchmarking
13.5.6.4. Strategic Initiatives
13.5.7. Bristol-Myers Squibb Company
13.5.7.1. Overview
13.5.7.2. Financial Performance
13.5.7.3. Product Benchmarking
13.5.7.4. Strategic Initiatives
13.5.8. Sanofi
13.5.8.1. Overview
13.5.8.2. Financial Performance
13.5.8.3. Product Benchmarking
13.5.8.4. Strategic Initiatives
13.5.9. GSK plc.
13.5.9.1. Overview
13.5.9.2. Financial Performance
13.5.9.3. Product Benchmarking
13.5.9.4. Strategic Initiatives
13.5.10. AstraZeneca
13.5.10.1. Overview
13.5.10.2. Financial Performance
13.5.10.3. Product Benchmarking
13.5.10.4. Strategic Initiatives
13.5.11. Takeda Pharmaceutical Company Limited
13.5.11.1. Overview
13.5.11.2. Financial Performance
13.5.11.3. Product Benchmarking
13.5.11.4. Strategic Initiatives
13.5.12. Biogen
13.5.12.1. Overview
13.5.12.2. Financial Performance
13.5.12.3. Product Benchmarking
13.5.12.4. Strategic Initiatives
13.5.13. Eli Lilly and Company
13.5.13.1. Overview
13.5.13.2. Financial Performance
13.5.13.3. Product Benchmarking
13.5.13.4. Strategic Initiatives
13.5.14. Novo Nordisk A/S
13.5.14.1. Overview
13.5.14.2. Financial Performance
13.5.14.3. Product Benchmarking
13.5.14.4. Strategic Initiatives
13.5.15. Amgen Inc.
13.5.15.1. Overview
13.5.15.2. Financial Performance
13.5.15.3. Product Benchmarking
13.5.15.4. Strategic Initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us